Pure Biologics

Pure Biologics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Pure Biologics (PUR.WA) as of Nov 12, 2026 is 63.93 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 55.72 % — a change of 14.74% (higher).

Cash Conversion

63.93 %

YoY

14.74%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Pure Biologics is 2025 63.93 % . Cash Conversion Rate (OCF/Net Income) of Pure Biologics was 2024 55.72 % . It decreases by 14.74% higher compared to the previous year.

The Pure Biologics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
360.91 PLN
Jan 1, 2019
-113.39 PLN
Jan 1, 2020
11.18 PLN
Jan 1, 2021
183.88 PLN
Jan 1, 2022
65.93 PLN
Jan 1, 2023
65.17 PLN
Jan 1, 2024
55.72 PLN
Jan 1, 2025
63.93 PLN
The Pure Biologics Cash Conversion history
YEARCash ConversionYoY
63.93 %+14.74%
55.72 %-14.50%
65.17 %-1.15%
65.93 %-64.15%
183.88 %+1,545.14%
11.18 %-109.86%
-113.39 %-131.42%
360.91 %-47.72%
690.36 %+320.81%
164.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

Cash Conversion Rate (OCF/Net Income) of Pure Biologics is 63.93 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Pure Biologics changed from 55.72 % to 63.93 %, representing a 14.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Pure Biologics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Pure Biologics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pure Biologics